title: Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy.
abstract: A trial to evaluate the safety and immunogenicity of recombinant modified vaccinia Ankara (MVA) and fowlpox (FP) vectors expressing multiple HIV-1 proteins was conducted in twenty HIV-1 infected youth with suppressed viral replication on HAART. The MVA and FP-based multigene HIV-1 vaccines were safe and well tolerated. Increased frequencies of HIV-1 specific CD4+ proliferative responses and cytokine secreting cells were detected following immunization. Increased frequencies and breadth of HIV-1 specific CD8 T-cell responses were also detected. Plasma HIV-1-specific antibody levels and neutralizing activity were unchanged following vaccination. Poxvirus-based vaccines may merit further study in therapeutic vaccine protocols.
authors.affiliation: Pediatrics and Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA. thomas.greenough@umassmed.edu
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Greenough
authors.forename: Coleen K
authors.initials: CK
authors.lastname: Cunningham
authors.forename: Petronella
authors.initials: P
authors.lastname: Muresan
authors.forename: Margaret
authors.initials: M
authors.lastname: McManus
authors.forename: Deborah
authors.initials: D
authors.lastname: Persaud
authors.forename: Terry
authors.initials: T
authors.lastname: Fenton
authors.forename: Piers
authors.initials: P
authors.lastname: Barker
authors.forename: Aditya
authors.initials: A
authors.lastname: Gaur
authors.forename: Dennis
authors.initials: D
authors.lastname: Panicali
authors.forename: John L
authors.initials: JL
authors.lastname: Sullivan
authors.forename: Katherine
authors.initials: K
authors.lastname: Luzuriaga
mesh_terms: D016915:AIDS Vaccines / Q000009:adverse effects* / Q000276:immunology*; D000293:Adolescent; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D016516:CD4-CD8 Ratio; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D005434:Flow Cytometry; D005587:Fowlpox virus / Q000276:immunology*; D015683:Gene Products, gag / Q000096:biosynthesis / Q000235:genetics; D015483:HIV Antibodies / Q000032:analysis / Q000096:biosynthesis; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D008297:Male; D011446:Prospective Studies; D012367:RNA, Viral / Q000032:analysis / Q000096:biosynthesis; D013601:T-Lymphocytes / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology; D014615:Vaccinia / Q000276:immunology; D055815:Young Adult
chemical_list: D016915:AIDS Vaccines; D016207:Cytokines; D015683:Gene Products, gag; D015483:HIV Antibodies; D012367:RNA, Viral; D014614:Vaccines, Synthetic; D007371:Interferon-gamma